Clinical features and outcome of MLL gene rearranged acute lymphoblastic leukemia in infants with additional chromosomal abnormalities other than 11q23 translocation.
The treatment outcome for infant acute lymphoblastic leukemia (ALL) with positive MLL gene rearrangements remains poor. We analyzed whether additional chromosomal abnormalities (ACA) other than 11q23 translocation could affect the disease behavior and its prognosis. Eighteen of seventy-four patients with infant acute lymphoblastic leukemia showed ACA, including three-way translocations in four, other novel translocations in four, and complex structural chromosomal changes in four. Only age less than 6 months and positive central nervous system leukemia were significant prognostic factors by multivariate analysis. However, overall survival rates were worse in patients with ACA compared to those with non-ACA. Genetic alterations induced by additional chromosomal changes may be associated with disease progression and poorer overall survival rates in infants with MLL-rearranged ALL.
Tauchi
Hisamichi
H
Department of Pediatrics, Ehime University, Toon, Ehime, Japan.
Tomizawa
Daisuke
D
Eguchi
Mariko
M
Eguchi-Ishimae
Minenori
M
Koh
Katsuyoshi
K
Hirayama
Masahiro
M
Miyamura
Noriko
N
Kinukawa
Naoko
N
Hayashi
Yasuhide
Y
Horibe
Keizo
K
Ishii
Eiichi
E
D002869:Chromosome Aberrations; D002880:Chromosomes, Human, Pair 11; D018572:Disease-Free Survival; D005260:Female; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000401:mortality* / Q000628:therapy; D015996:Survival Rate; D014178:Translocation, Genetic; D016896:Treatment Outcome
C497422:KMT2A protein, human; D051788:Myeloid-Lymphoid Leukemia Protein; D011495:Histone-Lysine N-Methyltransferase